Amoxicillin-associated hemorrhagic colitis in the presence of Klebsiella oxytoca.
Antibiotic-induced diarrhea can be a significant source of morbidity. Pseudomembranous colitis, or Clostridium difficile-associated diarrhea (CDAD), is an increasingly reported adverse effect of therapy with broad-spectrum antibiotics and can prolong the hospital stay of affected patients. Although sharing some of the same clinical symptoms as CDAD, antibiotic-associated hemorrhagic colitis is a distinctly separate form of colitis that is characterized by the absence of toxin-producing C. difficile and the presence of hematochezia. Colonoscopy usually reveals extensive hemorrhage and inflammation in the lamina propria, with lack of pseudomembranes. Spontaneous resolution usually occurs shortly after cessation of the antibiotic. Infection with Klebsiella oxytoca, a gram-negative facultative aerobic enterobacterium, has been suggested as a possible cause for antibiotic-associated hemorrhagic colitis. Some K. oxytoca strains isolated from patients with antibiotic-associated hemorrhagic colitis produce a cytotoxin that can induce epithelial cell death and may predispose certain patients to hemorrhagic colitis during exposure to antibiotics. We describe a patient who developed hemorrhagic colitis shortly after starting a course of amoxicillin therapy for sinusitis prophylaxis. His stool samples were negative for C. difficile antigens but grew K. oxytoca. The patient received supportive care in conjunction with antibiotic coverage consisting of metronidazole and piperacillin-tazobactam. He improved throughout his hospital stay and was discharged on hospital day 11. Given the increasing concern for CDAD, clinicians should be careful not to overlook other possible causes for antibiotic-induced diarrhea.
Philbrick
Ann M
AM
Department of Pharmaceutical Care, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Ernst
Michael E
ME
D000658:Amoxicillin / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D004761:Enterocolitis, Pseudomembranous / Q000139:chemically induced* / Q000382:microbiology; D006801:Humans; D007710:Klebsiella Infections / Q000175:diagnosis / Q000209:etiology*; D041121:Klebsiella oxytoca / Q000302:isolation & purification; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010878:Piperacillin / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D012852:Sinusitis / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D008795:Metronidazole; D000077725:Piperacillin, Tazobactam Drug Combination; D000658:Amoxicillin; D010397:Penicillanic Acid; D010878:Piperacillin